iA Global Asset Management Inc. Lowers Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

iA Global Asset Management Inc. decreased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 64.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 981 shares of the biotechnology company's stock after selling 1,789 shares during the quarter. iA Global Asset Management Inc.'s holdings in United Therapeutics were worth $352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Meiji Yasuda Asset Management Co Ltd. raised its holdings in shares of United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock valued at $652,000 after acquiring an additional 33 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock valued at $1,441,000 after acquiring an additional 37 shares in the last quarter. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock valued at $109,000 after acquiring an additional 42 shares in the last quarter. Finally, First Citizens Bank & Trust Co. raised its holdings in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock valued at $961,000 after acquiring an additional 48 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the firm's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the transaction, the chief financial officer now directly owns 6,978 shares of the company's stock, valued at approximately $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 15,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. The trade was a 85.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

NASDAQ UTHR traded down $0.08 during trading hours on Wednesday, hitting $362.16. The company's stock had a trading volume of 212,643 shares, compared to its average volume of 449,234. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The company's 50 day simple moving average is $369.40 and its two-hundred day simple moving average is $340.77. The company has a market cap of $16.17 billion, a P/E ratio of 15.91, a price-to-earnings-growth ratio of 1.07 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same period last year, the company earned $5.38 EPS. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on UTHR. Jefferies Financial Group upped their target price on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. Finally, HC Wainwright upped their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.